Atossa Therapeutics Inc (NASDAQ:ATOS) said during the third quarter it made significant advancements both as a company and across its proprietary oral formulation of (Z)-endoxifen research program.
The breast cancer-focused biopharmaceutical company on Monday said it has four ongoing Phase 2 studies evaluating (Z)-endoxifen, having achieved 80% enrolment in its Karisma and I-SPY trials.
“With two Phase 2 trials approaching full enrollment, we are preparing for expected data readouts in the second half of 2024,” Atossa CEO Dr. Steven Quay said in a statement.
“We also made important progress with our EVANGELINE study by initiating the 80mg PK run-in cohort and announced a fourth Phase 2 study in Ductal Carcinomia In Situ (DCIS), which like our trial in mammographic breast density, is investigating (Z)-endoxifen in a population of women who are at high risk of developing breast cancer.
“We expect data from these four ongoing Phase 2 trials to further strengthen the growing body of evidence that (Z)-endoxifen may play an important role in both the prevention and treatment of breast cancer.”
Atossa exited the third quarter with $94 million in cash and cash equivalents.
For the three months ended September 30, 2023, it narrowed its net loss from $8.07 million for the same period in 2022 to $6.23 million.
During this period, it had no source of sustainable revenue. Interest income for 3Q was $1,080, up from $194 in the year-ago quarter.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on X, formerly known as Twitter, @emilyjjarvie